Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).

Patients living farther from their treating clinic ( adj OR: 0.96; 0.93–0.99, P = .03) and in rural areas (model 2: adj OR: 0.64; 0.35–1.16, P = .14 and model 3: adj OR: 0.88; 0.56–1.39, P = .58) were less likely to be treated with IV bDMARD; however, for the residential area type the difference did not reach statistical significance.

also in 111,027 other papers